In the pivotal phase 3 clinical trial of a PARP inhibitor in pancreatic cancer with germline mutations in BRCA1/2 (POLO study), the drug was to be switched from mFOLFIRINOX to Ola in cases where the tumors remained non-progressive according to RECIST after at least 4 months of mFOLFIRINOX treatment (18). The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.